If RLYP mgt wanted to secure a secondary at a higher price, this was a brilliant move. Overnight, they are able to cash in and sell shares on the open market for 60% above their Thursday close.
But, if there is indeed a buyer lurking, then that's awesome too. I"m hoping for a premium buyout price, however, if they do not get the price that is reasonable, with the recent spike in price, they should be well off in filling their coffer with some serious cash.
Thumbs up to management.
PFE could seriously use a fine drug like Nuplizid to fill their pipeline. The indications will undoubtedly grow and off label use will turn this into a $4-5 billion dollar drug. No competition.
I think the company is working on a partnership agreement. This is likely why many analysts have a price target some 100-300% higher than the market price. The company has several options. Patience will pay off nicely. Let the MM's play with RLYP. It's in their hands now.
The data is quite convincing. The compound works. The study population in the recent PIII trial were folks who were the sickest of the sickest. In this population, a robust immune response can be the very cause of their demise. We see this in some AIDS patient who receive HAART therapy. Today's animal study further supports value for Brincidofovir.
Can any immunologist or infectious disease specialist comment on the strange events that can occur in the sickest of the sick patient population? The drugs seems very effective but the idea of GVHD...I haven't heard of any good explanation. I'm curious of the subset analysis that can be the basis for a future study.
Look. The movement here at this level is Shorts taking control of the overall Biotech weakness and squeezing BB out of their massive position. None of BB's Biotech bets have done nothing in the past 2 months but free fall. SGEN, BLCM, ACAD etc... ACAD should do well in the meeting. The safety profile is very clean.
The set up for ACAD will be something to look back to. Let's see who owns the 99% of the float. Who just bought up all of the secondary offering at $29? It appears to me that the price manipulation we are seeing is partly the exchange traded funds having to dump shares due to the recent market volatility. But, individual funds are adding. In the next month or so, I suspect JJ or BIIB buys out ACAD for their 2+ Billion dollar drug and for the pipeline that may make the buyer a company set for the next decade.
We'll wake up one morning and see a buyout offer at $40+. That will make for a nice 2016. Baker Bros are banking on ACAD.